Great Basin Scientific Inc. (fka GBSNQ)

[guidelines]

$GBSN REAL DD - Facts not Fiction: HERE IS WHY $GBSN IS GOING RIGHT BACK UP - SO BUY THE FEAR TODAY WHILE SHARES ARE CHEAP.

- GBSN's portable quick-result lab test system is best of breed - most cost/price competitive - all hospitals worldwide buying this hi-tech Dx test lab - because it SAVES HOSPITAL DAYS ($$$) AND PATIENT LIVES BY ACCURATELY IDENTIFYING STREP, STAPH, C-difficile, MRSAs, other deadly multi-drug resistant pathogens -

- GBSN 2016 revenue $3.2mil up 40% over 2015

- 2017 closed pipeline sales orders - $ 2.4mil - before yer even begins! Sales projected to potentially increase 100-200% in 2017 and 2018

- 2 new FDA 510k applications for new Infection ASSAY to be approved 1st Half 2017

- A/S is now 1.5bil shares -

Tired of the agenda-driven opinions on the board? Want to make a massive ROI (profit)? Want to get the facts?
Then go to the SEC filings and read every single filing like I did, including the two major recent press releases.

https://gbscience.com/great-basin-scientific-announces-preliminary-fourth-quarter-2016-revenue/

https://www.barchart.com/stocks/quotes/GBSND#/news/87054/great-basin-announces-request-to-withdraw-s-1-registration-statement-and-amendment-to-75-million-2016-convertible-note

Fourth Quarter 2016 Financial Results and Business Highlights:

Revenue increased 39.2% to $851,930 compared with the same quarter in 2015;
Revenue increased 15.8% over the third quarter 2016;
2016 revenue was $3,048,126 up 42.3% over fiscal year 2015;
Group B. Strep test revenue increased 274% to $150,570 compared with a year ago, and 38.5% quarter over quarter;
Newly launched Shiga Toxin Direct Test and Staph ID/R Blood Culture Panel revenues were $51,720 combined; and
Submitted 510(k) application for Stool Pathogens Panel to the FDA.
“We are very pleased to see the return of quarter-over-quarter revenue growth, which we view — along with the significant funnel of new business in evaluation or scheduled for evaluation —as a strong indicator of the growth ahead in 2017,” said Ryan Ashton, co-founder and chief executive officer of Great Basin Scientific. “For much of 2016, we had a limited product offering, and because of that limitation, growth of new business was only able to keep up with the seasonal decline of C. diff testing rates. However, since launching our Staph ID/R Blood Culture Panel and Shiga Toxin Direct Test, we are seeing significant progress in placing the Great Basin system at medium-to-large hospitals and labs, which is leading to better utilization of instruments and accelerating revenue growth. The interest in both our current menu of four products along with the two additional assays we expect to have FDA-cleared later this year, has exceeded our expectations. We are looking forward to a year of strong and accelerating revenue growth.”

New Business Funnel and Product Mix

At January 20, the Company had roughly $2.54 million in expected new business in the New Business sales funnel. These revenue estimates, as well as those below, are based on the evaluating site’s own estimate of their expected testing volumes multiplied by the product price offered to the prospective customer. The Company is particularly pleased with its success in placing its higher value Staph ID/R (SIDR) panel with new and existing customers. Staph ID/R has a list price 50% above that of the Company’s low-plex tests, with the same cost-of-goods, offering the potential of improved gross margins for the Company as the panel becomes a significant portion of the Company’s product mix. The New Business sales funnel follows: